• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Morphotek - Articles and news items

First patient enrolled in trial of amatuximab in mesothelioma

Industry news / 18 November 2015 / Victoria White

Amatuximab is a monoclonal antibody (mAb) that triggers antibody-dependent cellular cytotoxicity against tumour cells expressing mesothelin…

 

Webinar: NIR Spectroscopy for Assessing Blend Uniformity in the Pharmaceutical IndustryLEARN MORE
+ +